Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

0.9642
-0.0458-4.53%
Volume:200.83K
Turnover:195.20K
Market Cap:14.54M
PE:-0.06
High:1.00
Open:0.9700
Low:0.9500
Close:1.01
Loading ...

Allarity appoints Jeff Ervin as CFO

TIPRANKS
·
Yesterday

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

GlobeNewswire
·
Yesterday

Allarity Therapeutics Inc. Announces Australian Patent Acceptance for Stenoparib DRP® Companion Diagnostic

Reuters
·
30 Jun

BRIEF-Allarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer

Reuters
·
27 Jun

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

THOMSON REUTERS
·
27 Jun

Allarity Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
18 Jun

Allarity Therapeutics Appoints Jesper Høiland to Board of Directors, Succeeding Joseph Vazzano

Reuters
·
12 Jun

BRIEF-Allarity Therapeutics Announces Changes To Board Of Directors

Reuters
·
12 Jun

Allarity Therapeutics Announces Changes to Board of Directors

THOMSON REUTERS
·
12 Jun

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

GlobeNewswire
·
04 Jun

Allarity Therapeutics Launches New Phase 2 Clinical Trial for Stenoparib in Advanced Ovarian Cancer

Reuters
·
02 Jun

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

TIPRANKS
·
02 Jun

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

THOMSON REUTERS
·
02 Jun

Allarity Therapeutics Inc - Trial Expected to Generate Significant Data by Late Summer 2026

THOMSON REUTERS
·
02 Jun

Allarity Therapeutics Q1 EPS $(0.25) Up From $(22.14) YoY

Benzinga
·
10 May

Allarity Therapeutics Inc - as of March 31, 2025, Cash, Cash Equivalents and Restricted Cash Totaled $27.7 Mln

THOMSON REUTERS
·
10 May

Allarity Therapeutics Q1 Operating Expenses USD 3.036 Million

THOMSON REUTERS
·
10 May

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert

Benzinga
·
01 Apr

BRIEF-Allarity Therapeutics Cash & Cash Receivable Balance Of $20.9 Million As Of Dec 31, Expected To Fund Operations, Including Clinical Activities Into 2027

Reuters
·
01 Apr

Allarity Therapeutics FY 2025 GAAP EPS $(15.65) Beats $(46.80) Estimate

Benzinga
·
01 Apr